• 1
    Hedner U. Recombinant coagulation factor VIIa: from concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26: 363366.
  • 2
    Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331334.
  • 3
    Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break with tradition in need of controlled trials. HEPATOLOGY 2004; 39: 592598.
  • 4
    Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for end-stage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10: 9951000.
  • 5
    Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Marigrazia C, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. HEPATOLOGY 2005; 41: 553558.
  • 6
    Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958965.
  • 7
    Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. HEPATOLOGY 1996; 24: 11371142.
  • 8
    Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89: 273293.
  • 9
    Lisman T, Bongers T, Adelmeijer J, Janssen H, de Maat M, de Groot P, Leebeck F. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. HEPATOLOGY 2006; 44: 5361.
  • 10
    Hollestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267275.
  • 11
    Francis JL, Armstrong DJ. Acquired dysfibrinogenemia in liver disease. J Clin Pathol 1982; 35: 667672.
  • 12
    Langer DA, Shah VH. Nitric oxide and portal hypertension: Interface of vasoreactivity and angiogenesis. J Hepatol 2006; 44: 209216.
  • 13
    Oksuzoglu G, Simsek H, Haznedaroglu IC, Kirazli S. Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Am J Gastroenterol 1997; 92: 303306.
  • 14
    Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101: 13821390.
  • 15
    Violi F. Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica 1994; 79: 6165.
  • 16
    Hu K-Q, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 15811586.
    Direct Link:
  • 17
    Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999; 94: 25692574.
  • 18
    Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 16221627.
  • 19
    Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002; 37: 463470.
  • 20
    Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131139.
  • 21
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. HEPATOLOGY 2003; 38: 230237
  • 22
    Papatheodoridis GV, Patch D, Webster GJM, Brooker J, Barnes E, Burroughs AK. Infection and hemostasis in decompensated cirrhosis: a prospective study using thromboelastography. HEPATOLOGY 1999; 29: 10851090.
  • 23
    Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation and variceal bleeding in cirrhosis. Gut 2005; 54: 556563.
  • 24
    Agarwal S, Joyner KA, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95: 32183224.
    Direct Link:
  • 25
    Ben Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94: 29772982.
    Direct Link:
  • 26
    Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 28012803.
    Direct Link:
  • 27
    Polson J, Lee WM. AASLD position paper: The management of acute liver failure. HEPATOLOGY 2005; 41: 11791197
  • 28
    Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98: 11671174.
    Direct Link:
  • 29
    Brown RS Jr, Kumar KS, Russo MW, Kinkhabwala M, Rudow DL, Harren P, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002; 8: 278284.
  • 30
    Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994; 20: 531536.
  • 31
    Laffi G, Marra F. Complications of cirrhosis: Is the endothelium guilty? J Hepatol 1999; 30: 532535.
  • 32
    Boberg KM, Brosstad F, Egeland T, Egge T, Schrumpf E. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost 1999; 81: 378381.
  • 33
    de Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. HEPATOLOGY 1993; 18: 11021107.
  • 34
    Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388393.
  • 35
    Boks AL, Brommer EJP, Schalm SW, Van Vliet HHDM. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. HEPATOLOGY 1986; 6: 7986.
  • 36
    Mancuso A, Fung K, Cox D, Mela M, Patch D, Burroughs AK. Assessment of blood coagulation in severe liver disease using thromboelastography: use of citrate storage versus native blood. Blood Coagul Fibrinolysis 2003; 14: 211216.
  • 37
    AuBuchan JP. Meeting transfusion safety expectations. Ann Intern Med 2005; 143: 537538
  • 38
    Hendriks HG, Meijer K, de Wolf J, Porte RJ, Klompmaker IJ, Lip H, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002; 13: 309313.
  • 39
    Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 1997; 113: 19301937.
  • 40
    Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33: 883890.
  • 41
    Gunawan B, Runyon BA. The efficacy and safety of ϵ-aminocaroic acid treatment in patients with cirrhosis and hyperfibrinolysis. Alimentary Pharmacol Ther 2006; 23: 115120.
  • 42
    Hernandez AJ, Northup PG. Factor VII versus FFP for bleeding after liver biopsy: A cost-effectiveness evaluation. (Submitted)
  • 43
    Castelino DJ, Salem HH. Natural anticoagulants and the liver. J Gastroenterol Hepatol 1997; 12: 7783.
  • 44
    Sacerdoti D, Merkel C, Bolognesi M, Amodio P, Angeli P, Gatta A. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology 1995; 108: 11521158.
  • 45
    Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982; 99: 217230
  • 46
    Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thrombosis. Am J Gastroenterol 2006; 101: 15241528.
    Direct Link:
  • 47
    Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. HEPATOLOGY 2000; 31: 345348
  • 48
    Violi F, Ferro D, Basili S, D'Angelo A, Mazzola G, Quintarelli C, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ 1994; 309: 239240.
  • 49
    Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. HEPATOLOGY 1995; 21: 12381247.
  • 50
    Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension; a pathological study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 11631184.